24 results on '"Kurma, Keerthi"'
Search Results
2. MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways
3. Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?
4. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study
5. CD95L concatemers highlight different stoichiometries of CD95‐mediated apoptotic and non‐apoptotic pathways
6. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.
7. CD95L concatemers highlight different stoichiometries of CD95‐mediated apoptotic and nonapoptotic pathways.
8. In vitro cross-talk between metastasis-competent circulating tumor cells and platelets in colon cancer: a malicious association during the harsh journey in the blood
9. Mechanobiology and survival strategies of circulating tumor cells: a process towards the invasive and metastatic phenotype
10. Data from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
11. Supplementary Material and Method, Supplementary Tables 1-2, and Figure Legends from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
12. Figure S4 from Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
13. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
14. Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model
15. Chronic Intermittent Hypoxia Increases Cell Proliferation in Hepatocellular Carcinoma
16. DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma
17. Modèle animal de carcinome hépatocellulaire sur foie cirrhotique : description et utilisation pour essais thérapeutiques pré-cliniques
18. GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition
19. Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
20. Abstract 3717: Animal model of cirrhosis with hepatocellular carcinoma: A reliable tool for testing new therapies
21. GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.
22. Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
23. Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
24. Abstract 5124: GNS561 a new quinoline derivative inhibits the growth of hepatocellular carcinoma in a cirrhotic rat and human PDX orthotopic mouse models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.